phosphodiesterase 4d7 (pde4d7), for use as a marker for hormone-sensitive malignant prostate cancer; composition or method of data acquisition or immunoassay to diagnose, detect, monitor or predict hormone-sensitive malignant prostate cancer or to diagnose, detect, monitor or predict progression to hormone-sensitive malignant prostate cancer; use of pde4d7; immunoassay to discriminate between a benign prostate tumor and a hormone-sensitive malignant prostate cancer; method for identifying an individual for eligibility for hormone-sensitive malignant prostate cancer therapy; immunoassay to classify an individual or section of individuals with a hormone-sensitive malignant prostate cancer disease; inhibitory pharmaceutical composition for the treatment or prevention of hormone sensitive malignant prostate cancer; stimulatory pharmaceutical composition; and; use of a pde4d7 protein-specific antibody and / or a pde4d7 protein-specific antibody variant

摘要

phosphodiesterase 4d7 (pde4d7), for use as a marker for hormone-sensitive malignant prostate cancer; composition or method or method of data acquisition or immunoassay for diagnosing, detecting, monitoring or predicting hormone-sensitive prostate cancer or for diagnosing, detecting, monitoring or predicting progression to hormone-sensitive prostate cancer; use of pde4d7; immunoassay to discriminate between a benign prostate tumor and a hormone-sensitive malignant prostate cancer; method for identifying an individual for eligibility for hormone-sensitive malignant prostate cancer therapy; immunoassay to classify an individual or section of individuals with a hormone-sensitive malignant prostate cancer disease; inhibitory pharmaceutical composition for the treatment or prevention of hormone sensitive malignant prostate cancer; stimulatory pharmaceutical composition; and; Use of a pde4d7 protein-specific antibody and / or a pde4d7 protein-specific antibody variant The present invention relates to 4d7 phosphodiesterase (pde4d7) for use as a marker for hormone-sensitive malignant prostate cancer, wherein marker expression is increased by comparing expression in hormone-sensitive malignant prostate cancer tissue to expression - in normal tissue or benign prostate tumor tissue, and the use of pde4d7 as a diagnostic marker for prostate cancer malignant, hormone sensitive. The present invention also relates to a composition for diagnosing, detecting, monitoring or predicting hormone sensitive malignant prostate cancer, a corresponding detection method, a method for discriminating between benign and hormone sensitive prostate cancer and a data acquisition method as well as corresponding immunoassays. The present invention also relates to a method for identifying an individual for eligibility for hormone-sensitive malignant prostate cancer as well as an immunoassay to classify an individual with such prostate cancer. The present invention further visualizes pharmaceutical compositions and their use for the treatment of hormone sensitive malignant prostate cancer.